GlaxoSmithKline announced that the FDA has approved Fluarix Quadrivalent (quadrivalent influenza vaccine [types A and B]) for the immunization of children >3 years old and adults to prevent disease caused by seasonal influenza virus subtypes A and B.

Currently administered trivalent flu vaccines help protect against the two A virus strains most common in humans and the B strain expected to be predominant in a given year. Fluarix Quadrivalent is the first intramuscular vaccine to cover against the two A strains with additional coverage against a second B strain.   

GlaxoSmithKline will make Fluarix Quadrivalent available in time for the 2013–2014 flu season.

For more information call (888) 825-5249 or visit